News
-
AstraZeneca has announced the launch of its FluMist Home service for delivery of the FluMist intranasal influenza vaccine in the US for the 2025-26 flu season. In September 2024, the nasal vaccine was approved by the… Read more . . .
-
Proveca and Cessatech have announced the submission of a pediatric-use marketing authorization (PUMA) application for CT001 sufentanil / ketamine nasal spray for the treatment of pain in pediatric patients and said that the EMA has… Read more . . .
-
Copley Scientific has announced the launch of its new Inhalytix+ subscription-based cascade impactor software package. The original Inhalytix software was introduced in 2021. According to the company, the new software can be integrated with testing equipment… Read more . . .
-
According to Tiziana Life Sciences, the FDA has approved the company’s IND for a Phase 2a trial of intranasal foralumab in patients with multiple system atrophy (MSA). The company is currently developing intranasal foralumab for the… Read more . . .
-
MannKind Corporation announced a strategic financing agreement with Blackstone that will provide the company with a $75 million loan initially, with a total potential of up to $500 million. MannKind said that the agreement was made in… Read more . . .
-
Ethris has announced the initiation of a Phase 2a trial of its intranasal ETH47 mRNA-based antiviral in asthma patients. The Phase 2a study is expected to enroll 50 adult patients who will receive either ETH47 or… Read more . . .
-
Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development… Read more . . .
-
AeroRx Therapeutics announced that a Phase 2a trial of its AERO-007 indacaterol / glycopyrrolate inhalation solution demonstrated statistically significant improvements FEV1 versus placebo for both doses studied. According to the company, the inhalation solution is… Read more . . .
-
Rocket Science Health, which recently partnered with Kindeva on development of its nasal delivery device, announced that the US Patent and Trademark Office (USPTO) has issued the company US Patent No. 12,343,489, titled, “Intranasal and… Read more . . .
-
GSK has announced that it will pay $500 million to Hengrui Pharma up front for the rights to Hengrui’s HRS-9821, an inhaled dry powder PDE3/4 inhibitor for the treatment of COPD, plus options to license… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland